Tag: Orladeyo
Nov 14, 2023 | 5 minutes read | All Posts
In December 2020, BCRX's Orladeyo made history as the first FDA-approved oral option to prevent hereditary angioedema (HAE) attacks. Despite being la...
Learn MoreStay Ahead of the Curve: Join Our Global Community and Get Access to Exclusive Consumer Market Insights, Industry Ranking Reports, Product News, and Market Updates from the Consumer Edge Insight Center